Amphastar Director Sells 16,679 Shares for $441,800 [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
These 10 stocks could mint the next wave of millionaires › Floyd Petersen, director of Amphastar Pharmaceuticals (NASDAQ:AMPH) , exercised 16,679 options for common stock and immediately sold all resulting shares in a transaction valued at $441,836.72, as disclosed in a SEC Form 4 filing Metric Value Shares sold Transaction value ~$441,800 Post-transaction shares Post-transaction value (direct ownership) ~$2 million Transaction value based on SEC Form 4 weighted average purchase price ($26.49); post-transaction value based on Nov. 13, 2025 market close ($26.37). How does the size of this transaction compare to Petersen's historical selling activity? The sale of 16,679 shares on November 13, 2025, is materially larger than the historical median sell-only transaction of 500 shares. What is the derivative context of this transaction? All 16,679 shares sold originated from the exercise of fully vested stock options, with immediate disposition in the open marke
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Will FDA Approval of an In-House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? [Yahoo! Finance]Yahoo! Finance
- Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile [Seeking Alpha]Seeking Alpha
- 2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at Barclays PLC to a "hold" rating.MarketBeat
- Amphastar Pharmaceuticals (NASDAQ:AMPH) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $30.00 price target on the stock.MarketBeat
AMPH
Earnings
- 11/6/25 - Beat
AMPH
Sec Filings
- 12/18/25 - Form 4
- 12/15/25 - Form 4
- 12/11/25 - Form 144
- AMPH's page on the SEC website